Abstract
Infants and children have historically received a weight-based escalating defibrillation dose, commencing at 2J/kg. Researchers are increasingly suggesting that 2J/kg maybe an ineffective initial defibrillation dose. However without a definitive study there has been hesitancy to modify this initial dose. The International Liaison Committee on Resuscitation made a recommendation in 2010 of an initial dose of 2–4 J/Kg, increased from 2 J/Kg. The American Heart Association and the European Resuscitation Councils now have different initial dosing recommendations for children. The ERC advocates 4J/kg as the initial dose without escalation for subsequent shocks, while the AHA recommends 2–4 J/Kg, increasing to ≥ 4 J/Kg with subsequent shocks up to adult dose. The difficulty of finding a dose based on robust evidence continues to provide a stimulus for research to better define the best defibrillation energy dose for children.
Keywords: Arrest, defibrillation, child, countershock, resuscitation.
Current Pediatric Reviews
Title:Defibrillation in Children: Why a Range in Energy Dosing?
Volume: 9 Issue: 2
Author(s): Jonathan Egan and Dianne L. Atkins
Affiliation:
Keywords: Arrest, defibrillation, child, countershock, resuscitation.
Abstract: Infants and children have historically received a weight-based escalating defibrillation dose, commencing at 2J/kg. Researchers are increasingly suggesting that 2J/kg maybe an ineffective initial defibrillation dose. However without a definitive study there has been hesitancy to modify this initial dose. The International Liaison Committee on Resuscitation made a recommendation in 2010 of an initial dose of 2–4 J/Kg, increased from 2 J/Kg. The American Heart Association and the European Resuscitation Councils now have different initial dosing recommendations for children. The ERC advocates 4J/kg as the initial dose without escalation for subsequent shocks, while the AHA recommends 2–4 J/Kg, increasing to ≥ 4 J/Kg with subsequent shocks up to adult dose. The difficulty of finding a dose based on robust evidence continues to provide a stimulus for research to better define the best defibrillation energy dose for children.
Export Options
About this article
Cite this article as:
Egan Jonathan and Atkins Dianne L., Defibrillation in Children: Why a Range in Energy Dosing?, Current Pediatric Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573396311309020006
DOI https://dx.doi.org/10.2174/1573396311309020006 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nephrotoxicity of Bisphenol A (BPA) -An Updated Review
Current Molecular Pharmacology MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets The Role of dUTPase and Uracil-DNA Repair in Cancer Chemotherapy
Current Protein & Peptide Science The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Subject Index To Volume 2
Current Cardiology Reviews A Chemical Genetics Approach for Specific Differentiation of Stem Cells to Somatic Cells: A New Promising Therapeutical Approach
Combinatorial Chemistry & High Throughput Screening Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry Cell-penetrating Peptides as Nucleic Acid Delivery Systems: From Biophysics to Biological Applications
Current Pharmaceutical Design Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Functional Effects of Levosimendan in Rat Basilar Arteries In Vitro
Current Neurovascular Research Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Effects of Statins on Transplant Graft Arterial Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Increased Neuronal Injury in Transgenic Mice with Neuronal Overexpression of Human Cyclooxygenase-2 is reversed by Hypothermia and Rofecoxib Treatment
Current Neurovascular Research Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Sudden Unexpected Death in Infancy (SUDI) — The Role of the Pathologist
Current Pediatric Reviews